Differences in the Coagulation Profile in Women with Mild and Severe Preeclampsia

Blood ◽  
2020 ◽  
Vol 136 (Supplement 1) ◽  
pp. 15-16
Author(s):  
Elmina Lefkou ◽  
Patrick Van Dreden ◽  
Aurélie Rousseau ◽  
Grigorios T. Gerotziafas
Keyword(s):  
Pregnant Women ◽  
Prothrombin Time ◽  
Cell Activation ◽  
Severe Preeclampsia ◽  
Clotting Time ◽  
Endothelial Cell Activation ◽  
Mild Preeclampsia ◽  
The Mean ◽  
Group D ◽  
D Dimer

Introduction:Different coagulations abnormalities have been referred in women with early oncet preeclampsia (EOP), but there are only few studies comparing those changes regarding to the severity of the disease. Aim:In this study we aimed to investigate the differences between the coagulation profile in women with mild and severe preeclampsia. Methods:This is an observational retrospective case-control study. Plasma samples were collected from 84 women divided into three groups, the healthy pregnant (HP) group (n=35), the mild preeclampsia (MP) group (n=34) and the severe preeclampsia (SP) group (n=15). The study population general characteristics are shown in Table 1. We studied the following biomarkers of hypercoagulability and endothelial cell activation: Tissue factor activity (TFa), Procoagulant phospholipid activity (PPL), Protein S, D-Dimers, Antithrombin, thrombomodulin, TFPI levels. All women were assessed with classic coagulation tests (aPTT and PT) fibrinogen levels and hemogram. Statistical analysis was performed using the PASW Statistics 17.0.2 (SPSS Inc.) for Windows. Results:Women with preeclampsia - mild or severe- showed significant increase of TFPI, TFa and TMa levels as compared to healthy pregnant women. No significant difference of TFPI, TFa was observed between MP and SP groups. In contrast, TMa levels were significantly increased in SP as compared to MP group. The ratio TFa/TFPI was also lower in SP as compared to MP-group. Women in MP or SP group had similarly shorter PPL clotting time as compared to HP group. D-dimer levels were increased in women with preeclampsia as compared to the HP group. D-Dimer levels were significantly higher in SP as compared to MP group. The levels of free PS activity in HP as well as MP and SP groups were lower than normal range in non-pregnant women and the value in MP was significantly lower than that of the HP or SP. Fibrinogen levels were not significantly different in the three studied groups of pregnant women. Prothrombin time was found to be increased in cases as compared to that in the controls. The mean value of prothrombin time in mild preeclampsia was 13.24±0.80 seconds and in severe preeclampsia it was seconds 14.77±0.96 and in pregnant controls 12.23±0.59 seconds (p<0.05 and p<0.001 respectively). The mean prothrombin time was found to increase with increasing severity of disease (p<0.001). The mean activated partial thromboplastin time were increased in mild preeclampsia and was 32.64±1.83 seconds and in severe preeclampsia it was 35.59±1.53 seconds and in pregnant controls 29.53±1.62 seconds (p<0.001). The activated partial thromboplastin time was found to increase with increasing severity of disease (p<0.001). The antithrombin III decreased in severe SP and MP or compared to pregnant controls (76.33±4.32 and 88.06±9.68 versus 95.40±0.36 respectively; p<0.001). This decrease is more pronounced in SP compared to MP (p<0.001). Conclusions:Preeclampsia is associated with endothelial cell activation as documented by the increase of TFa, soluble TM levels and TFPI levels in plasma. Release of soluble thrombomoduline and TFPI rather than TFa by endothelial cells appear to be related with degree of preeclampsia severity. Women with preeclampsia showed marked decrease of PPL clotting time indicating enhanced platelet activation that was independent of the severity of preeclampsia. In contrast, women with severe preeclampsia showed signs of enhanced hypercoagulability documented by the increase of D-dimer levels consumption of natural coagulation inhibitors and particularly of AT. This phenomenon tended to be reflected on the prolongation of PT and aPTT in women with severe preeclampsia. Disclosures No relevant conflicts of interest to declare.

scholarly journals Cystatin C Serum Level and the Severity of Preeclampsia

2017 ◽  
pp. 133
Author(s):  
Abraham Winarto ◽  
Eddy Suparman ◽  
John Wantania
Keyword(s):  
Serum Level ◽  
Serum Concentration ◽  
Pregnant Women ◽  
Cystatin C ◽  
Statistical Test ◽  
Severe Preeclampsia ◽  
Cross Sectional ◽  
Mild Preeclampsia ◽  
The Mean ◽  
Cross Sectional Design

Objective: Determining the cystatin C serum level among normotensive, mild preeclamptic, severe preeclamptic pregnant women and their relationship with the severity of preeclampsia. Method: The study was held using cross sectional design in Prof. Dr. RD Kandou Hospital in Manado and its network hospitals. We did on 51 samples at term pregnant women, consisting of 17 samples for each group in normotensive, mild preeclampsia, and severe preeclampsia. The data were analyzed using SPSS version 22.0 software through ANOVA and Kruskal Wallis statistical test. Result: The mean cystatin C serum concentration in normotensive pregnant women, mild preeclampsia, and severe preeclampsia were 0.82 mg/l, 1.03 mg/l, and 1.32 mg/l; respectively. The ANOVA statistical test showed the significant association between cystatin C level and severity of preeclampsia (p

scholarly journals Salmon consumption by pregnant women reduces ex vivo umbilical cord endothelial cell activation

2011 ◽  
Vol 94 (6) ◽  
pp. 1418-1425 ◽  
Author(s):  
Lieke WJ van den Elsen ◽  
Paul S Noakes ◽  
Martin A van der Maarel ◽  
Lefkothea-Stella Kremmyda ◽  
Maria Vlachava ◽  
...  
Keyword(s):  
Endothelial Cell ◽  
Pregnant Women ◽  
Umbilical Cord ◽  
Cell Activation ◽  
Ex Vivo ◽  
Endothelial Cell Activation

scholarly journals Prospective Assessment of Biomarkers of Hypercoagulability in Oncological Patients and Healthcare Workers Following Vaccination Against Sars-Cov-2 with the mRNA Vaccine. the Roadmap-COVID-19-Vaccin Study

Blood ◽  
2021 ◽  
Vol 138 (Supplement 1) ◽  
pp. 3207-3207
Author(s):  
Patrick Van Dreden ◽  
Joseph Gligorov ◽  
Evangelos Terpos ◽  
Mathieu Jamelot ◽  
Michele Sabbah ◽  
...  
Keyword(s):  
Endothelial Cell ◽  
Tissue Factor ◽  
Platelet Activation ◽  
Research Funding ◽  
Thrombin Generation ◽  
Cell Activation ◽  
Control Group ◽  
Clotting Time ◽  
Endothelial Cell Activation ◽  
Active Cancer

Abstract Background: COVID-19 has been associated with hypercoagulability, endothelial cell injury and frequent thrombotic complications resulting both from direct effects of the virus on the endothelium and from the 'cytokine storm' resulting from the host's immune response. Since the COVID-19 vaccines have been shown to effectively prevent symptomatic infection including hospital admissions and severe disease, the risk of COVID-19-related thrombosis should be expected to (almost) disappear in vaccinated individuals. However, some rare cases of venous thrombosis have been reported in individuals vaccinated with mRNA vaccines. Thus, there is a sharp contrast between the clinical or experimental data reported in the literature on COVID-19 and on the rare thrombotic events observed after the vaccination with these vaccines. This phenomenon raised some scepticism of even some fear about the safety of these vaccines which could compromise the adhesion of the citizens in the vaccination program. Aims: We conducted a prospective observational study, to explore the impact of vaccination with the BNT162b2 (Pfizer/BioNTech) on blood hypercoagulability and endothelial cell activation and to investigate if this is modified by the presence of active cancer. Methods: In total 229 subjects were prospectively included in the study from April to June 2021. Subjects were stratified in three predefined groups: 127 vaccinated patients with active cancer (VOnco group), 72 vaccinated health care workers (VHcw group) and 30 non vaccinated health individuals (Control group). Blood samples were obtained 2 days after the administration of the first dose of BNT162b2 vaccine and collected in Vacutainer® tubes (0.109 mol/L trisodium citrate). Platelet poor plasma (PPP) was prepared by double centrifugation at 2000 g for 20 minutes at room temperature and plasma aliquots were stored at -80°C until assayed. Samples of PPP were assessed for thrombin generation (TG) with PPP-Reagent® (Thrombogram-Thrombinoscope assay with PPP-Reagent®TF 5pM), E-selectin, D-dimers, (D-Di), Tissue Factor (TFa), procoagulant phospholipid-dependent clotting time (Procag-PPL) and von Willebrand factor (vWF), thrombomodulin (TM), tissue factor pathway inhibitor (TFPI), and platelet factor 4 (PF4). All assays were from Diagnostica Stago (France). The upper and lower normal limits (UNL and LNL) for each biomarker were calculated by the mean±2SD for the control group. Results: All vaccinated subjects showed significantly increased levels of PF4 (71% >UNL, p<0.001), D-Dimers (74% >UNL, p<0.01), vWF (60% >UNL, p<0.01), FVIII (62% >UNL, p<0.01) and shorter Procoag-PPL clotting time (96% <LNL, p<0.001), as compared to controls. Thrombin generation showed significantly higher Peak (60% >UNL, p<0.01), ETP (38% >UNL, p<0.01) and MRI (66% >UNL, p<0.01) but no differences in lag-time in vaccinated subjects as compared to the control group. Vaccinated subjects did not show any increase at the levels of TFa, TFPI, TM and E-selectin in comparison with the control group. The studied biomarkers were not significantly different between the VOnco and VHcw groups. Conclusion: The ROADMAP-COVID-19-Vaccine study shows that administration of the first dose of the BNT162b2 vaccine induced significant platelet activation documented by shorter Procoag-PPL associated with increased levels of PF4. Plasma hypercoagulability was less frequent in vaccinated individuals whereas there was no evidence of significant endothelial cells activation after vaccination. Interestingly, the presence of active cancer was not associated with an enhancement of platelet activation, hypercoagulability, or endothelial cell activation after the vaccination. Probably, the generated antibodies against the spike protein or lead to platelet activation in a FcyRIIa dependent manner that results in PF4 release. The implication of the mild inflammatory reaction triggered by the vaccination could be another possible pathway leading to platelet activation. Nevertheless, vaccination does not provoke endothelial activation even in patients with cancer. The findings of the ROADMAP-COVID-19-Vaccine study support the concept administration of mRNA based vaccines does not directly cause a systematic hypercoagulability. Disclosures Gligorov: Roche-Genentech: Research Funding; Novartis: Research Funding; Onxeo: Research Funding; Daichi: Research Funding; MSD: Research Funding; Eisai: Research Funding; Genomic Heatlh: Research Funding; Ipsen: Research Funding; Macrogenics: Research Funding; Pfizer: Research Funding. Terpos: Novartis: Honoraria; Janssen: Consultancy, Honoraria, Research Funding; Genesis: Consultancy, Honoraria, Research Funding; Celgene: Consultancy, Honoraria, Research Funding; BMS: Honoraria; Amgen: Consultancy, Honoraria, Research Funding; Takeda: Consultancy, Honoraria, Research Funding; Sanofi: Consultancy, Honoraria, Research Funding; GSK: Honoraria, Research Funding. Dimopoulos: Amgen: Honoraria; BMS: Honoraria; Janssen: Honoraria; Beigene: Honoraria; Takeda: Honoraria.

scholarly journals The Vascular Endothelium in Patients with Dengue Haemorrhagic Fever

2019 ◽  
Vol 7 (14) ◽  
pp. 2221-2225 ◽  
Author(s):  
Mutiara ◽  
Stephen C. L. Koh ◽  
Adang Bachtiar ◽  
Herman Hariman
Keyword(s):  
Vascular Endothelium ◽  
Cell Activation ◽  
Normal Subjects ◽  
Endothelial Activation ◽  
Dengue Haemorrhagic Fever ◽  
Haemorrhagic Fever ◽  
Endothelial Cell Activation ◽  
Study Results ◽  
Plasma Leakage ◽  
D Dimer

BACKGROUND: Dengue fever is the most serious consequence of mosquito-borne infection worldwide. The pathophysiology of DHF in human is complex, which involve endothelial cell activation and impaired endothelial barrier leading to plasma leakage triggering the activation of the haemostatic system. The increased vascular permeability may lead to hypovolemia, hypotension and shock, which is life-threatening. AIM: The objective of the study was to determine the effects of dengue haemorrhagic fever on the vascular endothelium. METHODS: Fifty patients (males 34, females 16), were recruited, Grade 1 (n = 41), Grade 2 (n = 6), Grade 3 (n = 2) and Grade 4 (n = 1) DHF. Blood sampling was performed at the febrile, defervescence and convalescent phases for the determination of haemoglobin, haematocrit, platelets, prothrombin fragment F1 + 2, Von Willebrand Factor (VWF), vascular endothelial growth factor (VEGF) and D-dimer levels. Fifteen normal subjects were recruited to serve as normal controls. RESULTS: The patients aged between 4 and 54 years old. Grades 1 & 2 DHF showed no significant differences in the parameters studied. However, thrombocytopenia, elevated F1 + 2, VWF, VEGF and D-dimer levels were evident in febrile, defervescence and convalescent phases suggesting endothelial activation and plasma leakage. Pleural effusion was observed only in severe DHF. The three patients with Grades 3 and 4 DHF had similar study results. No mortality was recorded in the study. CONCLUSION: In dengue haemorrhagic fever, the vascular endothelium is activated, causing plasma leakage triggering the activation of the haemostatic system creating a hypercoagulable and enhanced fibrinolytic state evident by marked fibrinolysis.

scholarly journals Do N-Terminal Pro-C-Type Natriuretic Peptide Levels Relate to Severity of Preeclampsia?

2020 ◽  
Vol 2020 ◽  
pp. 1-5
Author(s):  
Dogan Vatansever ◽  
Pınar Vatansever ◽  
Burak Giray ◽  
A. Aktug Ertekin ◽  
Serpil Bilsel
Keyword(s):  
Pregnant Women ◽  
Natriuretic Peptide ◽  
Venous Blood ◽  
Severe Preeclampsia ◽  
Study Group ◽  
Women Patients ◽  
Significant Difference ◽  
Mild Preeclampsia ◽  
Age Range ◽  
Circulating Levels

Aim. To compare the plasma N-terminal pro-C-type natriuretic peptide concentrations of normotensive pregnant women, patients with mild preeclampsia, and patients with severe preeclampsia. Methods. We collected venous blood samples from 25 normotensive pregnant women, 15 patients with mild preeclampsia, and 15 patients with severe preeclampsia. The women were at 30th to 40th weeks of gestation and in an age range of 20 to 35. The N-terminal pro-C-type natriuretic peptide levels were measured by ELISA. Statistical comparisons were made by one-way analysis of variance, Kruskal–Wallis, and Mann–Whitney U tests. Results. The median (interquartile range-IQR) values of the N-terminal pro-C-type natriuretic peptide were 6.48 (3.33) pmol/L in the normotensive women group, 7.37 (3.43) pmol/L in patients with mild preeclampsia, and 11.52 (6.13) pmol/L in patients with severe preeclampsia. The N-terminal pro-C-type natriuretic peptide was significantly elevated in the severe preeclampsia study group (P<0.001), whereas there was no significant difference between those with mild preeclampsia and the normotensive groups (P>0.05). Conclusion. Our data indicate that the plasma concentration of the N-terminal pro-C-type natriuretic peptide is significantly increased in patients with severe preeclampsia, but not in patients with mild preeclampsia. The severity of preeclampsia may be related to the circulating levels of the N-terminal pro-C-type natriuretic peptide concentrations.

scholarly journals Alterations of Several Serum Parameters Are Associated with Preeclampsia and May Be Potential Markers for the Assessment of PE Severity

2020 ◽  
Vol 2020 ◽  
pp. 1-7
Author(s):  
Zhongliang Duan ◽  
Cui Li ◽  
Wing Ting Leung ◽  
Jiangnan Wu ◽  
Mingyan Wang ◽  
...  
Keyword(s):  
Pregnant Women ◽  
Case Control Study ◽  
Lactic Dehydrogenase ◽  
Serum Levels ◽  
Retrospective Case ◽  
Distribution Width ◽  
Laboratory Markers ◽  
Mild Preeclampsia ◽  
Control Study ◽  
D Dimer

The precise pathophysiological mechanisms of preeclampsia (PE) and preventative strategies remain unknown. Laboratory markers which can help in identifying PE patients from pregnant women and assessing the severity of PE during pregnancy are worthy to be explored. In this study, a retrospective case-control study was designed to assess whether the serum levels of albumin (ALB), total protein (TP), prealbumin (PA), alkaline phosphatase (ALP), lactic dehydrogenase (LDH), D-dimer, fibrinogen (Fbg), platelet (PLT) count, mean platelet volume (MPV), and platelet distribution width (PDW) can help in assessing PE and evaluate its severity. 256 pregnant women were enrolled and classified into 3 groups: mild preeclampsia (mPE, n=85), severe preeclampsia (sPE, n=78), and healthy normotensive controls (control, n=93). Our result showed that the serum levels of ALP, LDH, and D-dimer were significantly higher in mild or severe PE patients compared with the healthy controls (66 (52.5-76.5) vs. 168 (141.5-201.25) vs. 182.5 (120-191.5), 152 (139.75-166.25) vs. 183.5 (163.25-307) vs. 282 (215.25-306), 1.05 (0.65-1.57) vs. 3.05 (2.25-4.08) vs. 5.65 (2.29-7.71)), while ALB, TP, and PA are lower (38 (37-42) vs. 31.5 (25.5-34.5) vs. 28.5 (24-33), 65 (63-68.25) vs. 56.5 (52-61) vs. 51.5 (49-58), 219.14±68.25 vs. 167.88±52.21 vs. 143.22±50.46). On the other hand, compared with the mPE group, the sPE group showed significantly lower PLT count but higher level of LDH, D-dimer, and Fbg. No significant differences in MPV or PDW were found between any of the two groups. In conclusion, the above markers except for the MPV and PDW may be correlated with PE severity in this patient cohort, indicating possible values of these potential biomarkers in auxiliary diagnosis and severity assessment of PE.

scholarly journals Increased Concentration of Soluble CD40 Ligand in Preeclampsia

2007 ◽  
Vol 13 (2) ◽  
pp. 201-205 ◽  
Author(s):  
Inci Alacacioglu ◽  
Mehmet Ali Ozcan ◽  
Ozden Piskin ◽  
Faize Yuksel ◽  
Ahmet Alacacioglu ◽  
...  
Keyword(s):  
Endothelial Cell ◽  
Inflammatory Response ◽  
Cell Activation ◽  
Disease Onset ◽  
Cd40 Ligand ◽  
Endothelial Cell Activation ◽  
Soluble Cd40 Ligand ◽  
Future Studies ◽  
Study Population ◽  
The Mean

Preeclampsia has been associated with increased platelet activation detected before disease onset. Platelets are involved in hemostasis and also directly initiate an inflammatory response of the vessel wall. Inappropriate activation of platelets may be involved in pathogenesis in preeclampsia by promoting coagulation and thrombosis, and also as a mediator of inflammation. Platelets may release inflammatory mediators such as soluble CD40 ligand. The plasma level of soluble CD40 ligand was investigated during preeclamptic (n =20) and normal pregnancies (n = 20) to emphasize inflammatory response in preeclampsia. The mean soluble CD40 ligand levels were 1.08 ± 0.43 ng/mL in patients with preeclampsia and 0.76 ± 0.24 ng/mL in healthy pregnant women, which was statistically significant ( P = .01). To clarify whether inflammation may cause inappropriate endothelial cell activation or inappropriate endothelial cell activation may start this inflammatory response, future studies are needed in a larger study population.

scholarly journals The comparison of creatinine and cystatin C value in preeclampsia severity and neonatal outcome

2018 ◽  
Vol 24 (3) ◽  
pp. 84 ◽  
Author(s):  
John Wantania ◽  
Abraham Winarto
Keyword(s):  
Cystatin C ◽  
Statistical Tests ◽  
Severe Preeclampsia ◽  
Neonatal Outcomes ◽  
Intrauterine Fetal Death ◽  
Adverse Neonatal Outcomes ◽  
C Value ◽  
Mild Preeclampsia ◽  
The Mean ◽  
Better Than

Objectives: to compare the levels of creatinine and cystatin C with the severity of preeclampsia, and assess neonatal outcomes.Materials and Methods: Creatinine, cystatin C, and neonatal outcomes were assesed in 17 normotensive samples, 17 samples of mild preeclampsia and 17 samples of severe preeclampsia. Analysis of data with statistical tests of ANOVA and t test differences between 2 proportions.Results: The mean levels of creatinine in the normotensive group, mild preeclampsia, severe preeclampsia are 0.56 mg/dL, 0.67 mg/ dL, and 0.75 mg/dL, p=0.138; While on cystatin C are 0.82 mg/L, 1.03 mg/L and 1.32 mg/L, p=0.000. The adverse neonatal out-come wasn’t found in the normotensive group. In mild pre-eclampsia obtained 1 preterm birth and 1 intrauterine fetal death (IUFD), whereas in severe preeclampsia obtained 3 babies born preterm, 1 IUFD, and 1 intrauterine growth restriction (IUGR).Conclusion: levels of cystatin C was increased significantly in line with increased severity of preeclampsia, whereas creatinine was not increased significantly. Cystatin C is better than crea-tinine as a marker of renal dysfunction in preeclampsia patients. There was an increase in adverse neonatal outcomes in the group of preeclampsia.

scholarly journals Study on serum Lipoprotein (a) level in preeclamptic Bangladeshi women

2009 ◽  
Vol 4 (2) ◽  
pp. 32-35
Author(s):  
Noor E-Ferdous ◽  
Mahmuda Khatun ◽  
Md Abu Siddique ◽  
Asma Ul Hosna ◽  
Shirin Akter Begum ◽  
...  
Keyword(s):  
Case Control Study ◽  
Serum Lipoprotein ◽  
Severe Preeclampsia ◽  
College Hospital ◽  
Lipoprotein A ◽  
Medical College ◽  
Mild Preeclampsia ◽  
The Mean ◽  
Average Serum ◽  
Control Study

It is a case control study which was design to know the association of serum Lipoprotein (a) level in preeclamptic (PE) in women. This study was carried out in department of Obstetrics and Gynecology, Sir Salimullah Medical College Hospital, Mitford, Dhaka. Total number of subjects was 100. Out of which 50 were cases and 50 were controls. Cases were physically and clinically proved PE patients. Controls were age, parity and gestational age matched. Three ml of blood were collected from each subjects, serum fasting LP(a) level were measured The mean age of study group was 24.49 ± 6.48 years. Serum Lipoprotein(a) level was 51.51 ± 29.38mg/dl Vs 17.40 ± 7.89 mg/dl in cases and controls respectively. This difference was statistically significant (p < 0.001). Mean serum Lipoprotein(a) level was found to be raised in severe preeclampsia (74.87mg/dl) and lowest in control subject Severe preeclampsia was found to be associated with higher level of lipoprotein (a) than both control (p < 0.01) and mild preeclamptic (p < 0.01) subjects. Mild preeclampsia was also found to have higher average serum Lipoprotein (a) than the normal (P < 0.01) subjects. Key Words: Lipoprotein(a), Preeclampsia, Bangladeshi women. doi:10.3329/uhj.v4i2.2073 University Heart Journal Vol. 4 No. 2 July 2008 p32-35

scholarly journals Correlation Between Nutritional Status of Pregnant Women Based on Upper Arm Circumference and Preeclampsia/Eclampsia Severity Degree at Jagir Public Health Center During January 2014 - March 2014

2018 ◽  
Vol 1 (2) ◽  
pp. 120
Author(s):  
Dian Nirmala Aprilia ◽  
Budi Prasetyo ◽  
Sulistiawati Sulistiawati
Keyword(s):  
Public Health ◽  
Nutritional Status ◽  
Pregnant Women ◽  
Health Center ◽  
Severe Preeclampsia ◽  
Upper Arm ◽  
Chi Square ◽  
Public Health Center ◽  
Arm Circumference ◽  
Mild Preeclampsia

Introduction: Preeclampsia/eclampsia is one of the causes of maternal mortality besides bleeding and infection. The exact etiology of this condition is still unknown. Nutritional status of pregnant women who are overweight can increase the risk. This study aims to determine the correlation between obesity and the severity of preeclampsia/eclampsia through upper arm circumference (UAC) measurement.Methods: This study is a cross-sectional analytic study. Data on preeclampsia/eclampsia and UAC obtained from patient medical records in Jagir Public Health Center Surabaya. Data were analyzed using Chi-square test.Results: Prevalence of mild preeclampsia was greater than severe preeclampsia (87.5% and 12.5%). The majority of patients with mild preeclampsia have normal UAC size (91.3%). Severe preeclampsia found higher in obesity group than normal nutritional status group (22.2% and 9.1%). From Chi-square test analysis, found that p = 0.557.Conclusion: There was no significant correlation between the nutritional status of pregnant women based on UAC measurement of and the severity of preeclampsia/eclampsia.

Sign in / Sign up

Export Citation Format

Share Document